- Name: Bin He
- Title: Associate Professor
- Email: hebin@sysucc.org.cn
- Phone:
My interest is to developnoveltechnologies fordecoding the dynamiccellular state and cell-cell organization, and toelucidate the cellular &molecular basis oforganized cellular structures in the early stages of tumorigenesis/metastasis.
2008 – 2012
1. Chen N#, Fang M#, Zhong L#, Li X, Zhou Y, Zhan J, Wang M, Fang Z, Wang H, Tang S, Liu F, Deng B, Chen N, Lei J, Zhang Y, Yan M, Zou Z, Gao Y, Chen C, Zhong W, Saladi SV, Ji H*, Liu Q*, Wang Z*,He B*. KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition.Cell Death Differ. 2026 Jan 8. doi: 10.1038/s41418-025-01657-7.
2. He B#, Gao R#, Lv SS#, Chen AL, Huang JX, Wang LX, Feng YX, Feng JS, Liu B, Lei J, Deng B, He B, Cui B, Peng F, Yan M, Wang ZF, Lam EW, Jin BL, Shao ZM, Li YL, Jiao JW, Wang X*, Liu Q*. Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness.Signal Transduct Target Ther. 2023; 8(1):275.
3. Wang Z# *, Liu F#, Chen N#, Wu J#, Li X#, Fang M, Yan M, Zhang J, Deng B, Wang L, Wang X, Liu M, Zeng D, Zou Z, Wang B, Songyang Z,He B*, Liu Q*. Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity.Nat Commun. 2025 Oct 21;16(1):9288.
4. Wen HJ#, Ma HJ#, Cai QC#, Lin SX#, Lei XX#,He B#, Wu SJ#, Wang ZF, Gao Y, Liu WS, Liu WP, Tao Q, Long ZJ, Yan M, Li DL, Kelley KW, Yang YL, Huang HQ, Liu Q*. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.Nat Med. 2018; 24(2):154-164.
5. He B#, Gao R#, Lv D, Wen Y, Song L, Wang X, Lin S, Huang Q, Deng Z, Wang Z1, Yan M, Zheng F, Lam EW, Kelley KW, Li Z*, Liu Q*. The Prognostic Landscape of Interactive Biological Processes Presents Treatment Responses in Cancer.EbioMedicine. 2019; 41, 120-133.
6. Peng F#, Xu J#, Cui B#, Liang QL#, Zeng S#,He B#, Zou H, Li MM, Zhao H, Meng YT, Chen J, Liu B, Lv SS, Chu P, An F, Wang ZF, Huang JX, Zhan YJ, Liao YW, Lu JX, Xu LZ, Zhang J, Sun ZL, Li ZG, Wang FJ, Lam EW and Liu Q*. Oncogenic AURKA-enhanced N6-methyladenosine Modification Increases DROSHA mRNA Stability to Transactivate STC1 in Breast Cancer Stem-like Cells.Cell Res. 2020; 31(3):345-361.
See comment in PubMed Commons below7. Yan M#, Zhang Y#,He B#, Xiang J, Wang ZF, Zheng FM, Xu J, Chen MY, Zhu YL, Wen HJ, Wan XB, Yue CF, Yang N, Zhang W, Zhang JL, Wang J, Wang Y, Li LH, Zeng YX, Lam EW, Hung MC, Liu Q*. IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation.Nat Commun. 2014; 5: 3661.
8. Li SS#, Qi YF#, Yu JC#, Hao YC#,He B#, Zhang MJ, Dai ZW, Jiang TH, Li SY, Huang F, Chen N, Wang J, Yang MY, Liang DP, An F, Zhao JY, Fan WJ, Pan YJ, Deng ZQ, Luo YY, Guo T, Peng F, Hou ZJ, Wang CL, Zheng FM, Xu LZ, Xu J, Wen QP, Jin BL*, Wang Y*, Liu Q*. Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4.Signal Transduct Target Ther. 2022;7(1):97.
9. Yan M#, Wang C#,He B#, Yang M, Tong M, Long Z, Liu B, Peng F, Xu L, Zhang Y, Liang D, Lei H, Subrata S, Kelley KW, Lam EW, Jin B*, Liu Q*. Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Med Res Rev. 2016; 36(6):1036-79.